About Maravai LifeSciences Holdings, Inc.
https://www.maravai.comMaravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally.
CEO
William E. Martin III
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 90
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Craig-Hallum
Buy
B of A Securities
Buy
RBC Capital
Outperform
Wells Fargo
Overweight
Morgan Stanley
Equal Weight
Baird
Neutral
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
GTCR LLC
Shares:20.15M
Value:$79.39M
12 WEST CAPITAL MANAGEMENT LP
Shares:12.52M
Value:$49.33M
BLACKROCK INC.
Shares:9.73M
Value:$38.33M
Summary
Showing Top 3 of 188
About Maravai LifeSciences Holdings, Inc.
https://www.maravai.comMaravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $41.63M ▼ | $-109.78M ▼ | $-25.56M ▲ | -61.39% ▲ | $0.48 ▲ | $-22.46M ▲ |
| Q2-2025 | $47.4M ▲ | $74.05M ▲ | $-39.59M ▼ | -83.53% ▼ | $-0.27 ▼ | $-51.92M ▼ |
| Q1-2025 | $46.85M ▼ | $56.89M ▼ | $-29.95M ▼ | -63.92% ▼ | $-0.21 ▼ | $-31M ▼ |
| Q4-2024 | $56.41M ▼ | $57.09M ▼ | $-26.14M ▲ | -46.35% ▲ | $-0.18 ▲ | $-20.71M ▲ |
| Q3-2024 | $65.2M | $197.49M | $-99.04M | -151.9% | $-0.7 | $-147.97M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $243.57M ▼ | $849.19M ▼ | $417.33M ▼ | $245.44M ▼ |
| Q2-2025 | $269.91M ▼ | $896.97M ▼ | $428.98M ▼ | $265.86M ▼ |
| Q1-2025 | $285.05M ▼ | $959.75M ▼ | $429.48M ▼ | $300.61M ▼ |
| Q4-2024 | $322.4M ▼ | $1.01B ▼ | $431.04M ▼ | $325.29M ▼ |
| Q3-2024 | $578.16M | $1.28B | $665.09M | $345.14M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-25.56M ▲ | $-15.15M ▼ | $-2.93M ▲ | $-8.25M ▼ | $-26.33M ▼ | $-18.08M ▼ |
| Q2-2025 | $-69.84M ▼ | $-10.27M ▼ | $-3.24M ▲ | $-1.53M ▲ | $-15.15M ▲ | $-13.14M ▲ |
| Q1-2025 | $-29.95M ▼ | $-9.39M ▲ | $-23.13M ▼ | $-4.9M ▲ | $-37.35M ▲ | $-14.63M ▲ |
| Q4-2024 | $-26.14M ▲ | $-14.64M ▼ | $-4.93M ▲ | $-236.19M ▼ | $-255.76M ▼ | $-20.49M ▼ |
| Q3-2024 | $-172.03M | $13.14M | $-8.96M | $809K | $4.99M | $3.54M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Biologics Safety Testing Segment | $30.00M ▲ | $20.00M ▼ | $20.00M ▲ | $20.00M ▲ |
 Nucleic Acid Production Segment | $100.00M ▲ | $30.00M ▼ | $30.00M ▲ | $30.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Asia Pacific | $50.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 EMEA | $30.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Latin And Central America | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 North America | $60.00M ▲ | $30.00M ▼ | $30.00M ▲ | $30.00M ▲ |
CEO
William E. Martin III
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 90
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Craig-Hallum
Buy
B of A Securities
Buy
RBC Capital
Outperform
Wells Fargo
Overweight
Morgan Stanley
Equal Weight
Baird
Neutral
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
GTCR LLC
Shares:20.15M
Value:$79.39M
12 WEST CAPITAL MANAGEMENT LP
Shares:12.52M
Value:$49.33M
BLACKROCK INC.
Shares:9.73M
Value:$38.33M
Summary
Showing Top 3 of 188